Findings

What do systematic reviews say?

7 questions · 7 findings · 1 reviews · Headline outcomes only

No studies found 2 · 28.6%GRADE not reported 0 · 0%Very low 1 · 14.3%Low 0 · 0%Moderate 4 · 57.1%High 0 · 0%

Progression to late AMD (neovascular AMD, geographic atrophy or both) · people with AMD

Zinc probably leads to lower progression to late AMD (neovascular AMD, geographic atrophy or both) compared with placebo (moderate certainty).

1 finding from 1 review

Progression to neovascular AMD · people with AMD

Zinc probably leads to lower progression to neovascular AMD compared with placebo (moderate certainty).

1 finding from 1 review

Progression to geographic atrophy · people with AMD

Zinc showed no clear difference in progression to geographic atrophy compared with placebo (moderate certainty).

1 finding from 1 review

Progression to visual loss (loss of 3 or more lines on logMAR chart) · people with AMD

Zinc showed no clear difference in progression to visual loss (loss of 3 or more lines on logMAR chart) compared with placebo (moderate certainty).

1 finding from 1 review

Quality of life · people with AMD

The review found no eligible studies for this question.

1 finding from 1 review

Adverse effects · people with AMD

1 finding from 1 review

Resource use and costs · people with AMD

The review found no eligible studies for this question.

1 finding from 1 review